Ventricular remodeling in heart failure with preserved ejection fraction

被引:50
作者
Shah A.M. [1 ]
机构
[1] Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA 02115
关键词
Echocardiography; Heart failure; Preserved Ejection Fraction; Ventricular Remodeling;
D O I
10.1007/s11897-013-0166-4
中图分类号
学科分类号
摘要
Heart failure with preserved ejection fraction (HFpEF) is common, increasing in prevalence, and causes substantial morbidity and mortality. HFpEF has commonly been viewed as an expression of advanced hypertensive heart disease, with a cardiac phenotype characterized by an increase in wall thickness-to-chamber radius ratio (concentric hypertrophy). However, marked clinical heterogeneity within this syndrome is now well appreciated, and is mirrored in the variability in left ventricular (LV) structure. A review of larger imaging studies from epidemiology and clinical trial cohorts demonstrate that while concentric LV remodeling is common, it is by no means universal and many patients demonstrate normal LV geometry or even an eccentric pattern. More detailed assessment of cardiac structure and function in broader HFpEF populations will be necessary to better define the prevalence, determinants, and prognostic relevance of these measures, which may in turn serve as a foundation to identify pathophysiologically relevant sub-phenotypes within this diverse syndrome. © 2013 Springer Science+Business Media New York.
引用
收藏
页码:341 / 349
页数:8
相关论文
共 67 条
  • [1] Bhatia R.S., Tu J.V., Lee D.S., Austin P.C., Fang J., Haouzi A., Et al., Outcome of heart failure with preserved ejection fraction in a population-based study, N Engl J Med, 355, pp. 260-269, (2006)
  • [2] Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction, N Engl J Med, 355, pp. 251-259, (2006)
  • [3] Tsutsui H., Tsuchihashi M., Takeshita A., Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function, Am J Cardiol, 88, pp. 530-533, (2001)
  • [4] Smith G.L., Masoudi F.A., Vaccarino V., Radford M.J., Krumholz H.M., Outcomes in heart failure patients with preserved ejection fraction: Mortality, readmission, and functional decline, J Am Coll Cardiol, 41, pp. 1510-1518, (2003)
  • [5] Vasan R.S., Larson M.G., Benjamin E.J., Evans J.C., Reiss C.K., Levy D., Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort, J Am Coll Cardiol, 33, pp. 1948-1955, (1999)
  • [6] Davis B.R., Kostis J.B., Simpson L.M., Black H.R., Cushman W.C., Einhorn P.T., Et al., Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial, Circulation, 118, pp. 2259-2267, (2008)
  • [7] Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J.V., Et al., Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial, Lancet, 362, pp. 777-781, (2003)
  • [8] Cleland J.G.F., Tendera M., Adamus J., Freemantle N., Polonski L., Taylor J., Et al., The perindopril in elderly people with chronic heart failure (PEP-CHF) study, Eur Heart J, 27, pp. 2338-2345, (2006)
  • [9] Massie B.M., Carson P.E., McMurray J.J., Komajda M., McKelvie R., Zile M.R., Et al., Ptaszynska A for the I-PRESERVE investigators, N Engl J Med, 359, pp. 2456-2467, (2008)
  • [10] Aurigemma G.P., Gaasch W.H., Diastolic heart failure, N Engl J Med, 351, pp. 1097-1105, (2004)